CBX3 and osteosarcoma: CBX3 overexpression was previously shown to promote tumor progression and to predict worse survival of lung [13,42], gastric [43], pancreatic, breast [11], glioma [44], osteosarcoma [45], liver [46], and kidney tumors [47].